Two Top Officials in FDA’s Vaccine Review Office to Retire
WEDNESDAY, Sept. 1, 2021 (HealthDay News) -- Two senior leaders in the U.S. Food and Drug Administration's vaccine review office are stepping down, but their departures won't slow efforts to combat the pandemic, the agency said Tuesday.
"We are confident in the expertise and ability of our staff to continue our critical public health work, including evaluating COVID-19 vaccines," FDA spokesperson Stephanie Caccomo told CNN.
The retirements of Dr. Marion Gruber, director of the Office of Vaccines Research and Review at FDA's Center for Biologics Evaluation and Research (CBER), and Dr. Philip Krause, deputy director of the office, come as the agency mulls decisions about COVID-19 vaccine approvals, authorizations for younger children and booster shots.
Gruber will retire on Oct. 31 and Krause will step down in November, according to an internal FDA email sent by CBER Director Dr. Peter Marks, CNN reported.
The search for the next director of the Office of Vaccines Research and Review will begin soon and Marks will serve as the acting director, the email explained.
Acting FDA Commissioner Dr. Janet Woodcock acknowledged to staff that the agency is operating in difficult times.
"Following today's announcement that Marion and Phil have decided to retire, I wanted to reach out to reiterate my full support and complete confidence in your ability to continue delivering on the agency's mandate to deliver safe, effective and high-quality vaccines to the American people," Woodcock said in an email to staff that was sent to CNN.
"The issues are complex and the days are long, but please know the work you all have done to date and will continue to do in the days, weeks and months ahead, will hopefully one day allow us to fully put COVID-19 behind us and better prepare us for future challenges," Woodcock added.
More information
Visit the U.S. Food and Drug Administration for more on COVID vaccines.
SOURCE: CNN
Related Posts
Respiratory Infections Temporally Linked to Kawasaki Disease
MONDAY, Feb. 7, 2022 (HealthDay News) -- Respiratory infections in children are...
Unos nuevos fármacos para perder peso se preparan para competir con Ozempic y Wegovy
LUNES, 26 de junio de 2023 (HealthDay News) -- Después de que la compañía...
AHA Issues Advisory for Penicillin Reactions in Patients With Severe RHD
WEDNESDAY, Feb. 2, 2022 (HealthDay News) -- For patients with rheumatic heart...
Anti-Reflux Mucosectomy Effective for GERD in Long Term
THURSDAY, June 29, 2023 (HealthDay News) -- For patients with gastroesophageal...